EMEA-001695-PIP01-14-M04

Key facts

Invented name
Delstrigo
Active substance
  • doravirine
  • lamivudine
  • tenofovir disoproxil (fumarate)
Therapeutic area
Infectious diseases
Decision number
P/0176/2021
PIP number
EMEA-001695-PIP01-14-M04
Pharmaceutical form(s)
  • Tablet
  • Granules
Condition(s) / indication(s)
Treatment of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Oral use
Contact for public enquiries
Merck Sharp & Dohme (Europe), Inc

Belgium
Tel. +33 180 464 738
E-mail: pip.information@merck.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating